Chemotherapeutic potential of phosphodiesterase inhibitors

This publication has 58 references indexed in Scilit:

• Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific Phosphodiesterase
  Biochemical and Biophysical Research Communications, 1998
• Identification, Quantitation, and Cellular Localization of PDE1 Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterases
  Methods, 1998
• Phosphodiesterase 4 inhibitors for the treatment of asthma
  Expert Opinion on Therapeutic Patents, 1997
• Neurotransmission and the contraction and relaxation of penile erectile tissues
  World Journal of Urology, 1997
• Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor
  Journal of Cardiovascular Pharmacology, 1996
• Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction
  Bioorganic & Medicinal Chemistry Letters, 1996
• Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram
  Cellular Signalling, 1996
• Characterization of Two Recombinant PDE3 (cGMP-Inhibited Cyclic Nucleotide Phosphodiesterase) Isoforms, RcGIP1 and HcGIP2, Expressed in NIH 3006 Murine Fibroblasts and Sf9 Insect Cells
  Biochemistry, 1996
• The role of phosphodiesterase inhibitors in heart failure
  Pharmacology & Therapeutics, 1993
• A New Cyclic Nucleotide Phosphodiesterase Isozyme Expressed in the T-Lymphocyte Cell Lines
  Biochemical and Biophysical Research Communications, 1993